These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 22542224

  • 1. The role of distal third radius dual energy X-ray absorptiometry (DXA) and central DXA in evaluating for osteopenia and osteoporosis in men receiving androgen deprivation therapy for prostate cancer.
    Sieber PR, Rommel FM, Theodoran CG, Russinko PJ, Woodward CA, Schimke L.
    J Clin Densitom; 2012; 15(3):351-4. PubMed ID: 22542224
    [Abstract] [Full Text] [Related]

  • 2. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ.
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [Abstract] [Full Text] [Related]

  • 3. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM, Ma JZ, Basler JW, Welch MD.
    Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
    [Abstract] [Full Text] [Related]

  • 4. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR.
    Cancer; 2004 Mar 01; 100(5):892-9. PubMed ID: 14983482
    [Abstract] [Full Text] [Related]

  • 5. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH, Frost M, Abrahamsen B, Brixen K, Walter S.
    Scand J Urol; 2014 Aug 01; 48(4):350-5. PubMed ID: 24548220
    [Abstract] [Full Text] [Related]

  • 6. Peripheral or axial bone density measurements to identify osteoporosis in prostate cancer patients undergoing androgen deprivation therapy?
    Wadhwa VK, Parr NJ.
    Urology; 2009 Jun 01; 73(6):1347-51. PubMed ID: 19362345
    [Abstract] [Full Text] [Related]

  • 7. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK, Weston R, Mistry R, Parr NJ.
    BJU Int; 2009 Sep 01; 104(6):800-5. PubMed ID: 19338564
    [Abstract] [Full Text] [Related]

  • 8. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
    Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.
    BJU Int; 2009 Dec 01; 104(11):1637-40. PubMed ID: 19549260
    [Abstract] [Full Text] [Related]

  • 9. Bone mineral density in rural Thai adults living in Khon Kaen province.
    Pongchaiyakul C, Rojroongwasinkul N, Chotmongkol R, Kosulwat V, Charoenkiatkul S, Rajatanavin R.
    J Med Assoc Thai; 2002 Feb 01; 85(2):235-44. PubMed ID: 12081125
    [Abstract] [Full Text] [Related]

  • 10. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E, Elliott ME.
    Ann Pharmacother; 2006 Dec 01; 40(12):2107-14. PubMed ID: 17132807
    [Abstract] [Full Text] [Related]

  • 11. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
    Deng J, Li W, Yang L, Wang L, Zou D.
    Zhonghua Nan Ke Xue; 2004 Oct 01; 10(10):761-3. PubMed ID: 15562791
    [Abstract] [Full Text] [Related]

  • 12. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.
    Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.
    Urology; 2007 Mar 01; 69(3):500-4. PubMed ID: 17382153
    [Abstract] [Full Text] [Related]

  • 13. The usefulness of dual energy X-ray and laser absorptiometry of the calcaneus versus dual energy X-ray absorptiometry of hip and spine in diagnosing manifest osteoporosis.
    de Klerk G, van der Velde D, van der Palen J, van Bergeijk L, Hegeman JH.
    Arch Orthop Trauma Surg; 2009 Feb 01; 129(2):251-7. PubMed ID: 18825395
    [Abstract] [Full Text] [Related]

  • 14. Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men.
    Zmuda JM, Cauley JA, Glynn NW, Finkelstein JS.
    J Bone Miner Res; 2000 Jul 01; 15(7):1417-24. PubMed ID: 10893693
    [Abstract] [Full Text] [Related]

  • 15. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME, Pundole X, Cabanillas G, Lei X, Zhao H, Elting LS, Lopez-Olivo MA, Giordano SH.
    JAMA Netw Open; 2022 Apr 01; 5(4):e225432. PubMed ID: 35363269
    [Abstract] [Full Text] [Related]

  • 16. Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer.
    Sullivan S, Wagner J, Resnick NM, Nelson J, Perera SK, Greenspan SL.
    J Clin Densitom; 2011 Apr 01; 14(3):348-53. PubMed ID: 21723763
    [Abstract] [Full Text] [Related]

  • 17. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.
    Prostate Cancer Prostatic Dis; 2002 Apr 01; 5(4):304-10. PubMed ID: 12627216
    [Abstract] [Full Text] [Related]

  • 18. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy.
    Tanvetyanon T.
    Cancer; 2005 Jan 15; 103(2):237-41. PubMed ID: 15597384
    [Abstract] [Full Text] [Related]

  • 19. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V, Reeves DJ.
    J Oncol Pharm Pract; 2012 Mar 15; 18(1):84-90. PubMed ID: 21807761
    [Abstract] [Full Text] [Related]

  • 20. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
    Deng JH, Yang LP, Wang LS, Zhou DF.
    Asian J Androl; 2004 Mar 15; 6(1):75-7. PubMed ID: 15064839
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.